NO981864L - Oppl°sningsmetoder - Google Patents

Oppl°sningsmetoder

Info

Publication number
NO981864L
NO981864L NO981864A NO981864A NO981864L NO 981864 L NO981864 L NO 981864L NO 981864 A NO981864 A NO 981864A NO 981864 A NO981864 A NO 981864A NO 981864 L NO981864 L NO 981864L
Authority
NO
Norway
Prior art keywords
sningsmetoder
upl
proteins
biologically active
active compounds
Prior art date
Application number
NO981864A
Other languages
English (en)
Other versions
NO981864D0 (no
Inventor
Roger Randal Charles New
Original Assignee
Cortecs Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cortecs Ltd filed Critical Cortecs Ltd
Publication of NO981864D0 publication Critical patent/NO981864D0/no
Publication of NO981864L publication Critical patent/NO981864L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A61K9/1075—Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/145—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Dispersion Chemistry (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)

Abstract

For bedre metoder for oppløsning av biologisk aktive forbindelser, for eksempel proteiner i et hydrofobt oppløsningsmiddel.
NO981864A 1995-10-25 1998-04-24 Oppl°sningsmetoder NO981864L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB9521805.3A GB9521805D0 (en) 1995-10-25 1995-10-25 Solubilisation methods
PCT/GB1996/002609 WO1997015289A1 (en) 1995-10-25 1996-10-25 Solubilisation methods

Publications (2)

Publication Number Publication Date
NO981864D0 NO981864D0 (no) 1998-04-24
NO981864L true NO981864L (no) 1998-06-24

Family

ID=10782854

Family Applications (1)

Application Number Title Priority Date Filing Date
NO981864A NO981864L (no) 1995-10-25 1998-04-24 Oppl°sningsmetoder

Country Status (12)

Country Link
EP (1) EP0857061A1 (no)
JP (1) JP2000502990A (no)
KR (1) KR19990067028A (no)
CN (1) CN1202818A (no)
AU (1) AU704292B2 (no)
BR (1) BR9611343A (no)
CA (1) CA2235487A1 (no)
GB (1) GB9521805D0 (no)
NO (1) NO981864L (no)
NZ (1) NZ320442A (no)
WO (1) WO1997015289A1 (no)
ZA (1) ZA969016B (no)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9605709D0 (en) * 1996-03-19 1996-05-22 Cortecs Ltd Method
US7731947B2 (en) 2003-11-17 2010-06-08 Intarcia Therapeutics, Inc. Composition and dosage form comprising an interferon particle formulation and suspending vehicle
WO2006083761A2 (en) 2005-02-03 2006-08-10 Alza Corporation Solvent/polymer solutions as suspension vehicles
US11246913B2 (en) 2005-02-03 2022-02-15 Intarcia Therapeutics, Inc. Suspension formulation comprising an insulinotropic peptide
EP2020990B1 (en) 2006-05-30 2010-09-22 Intarcia Therapeutics, Inc Two-piece, internal-channel osmotic delivery system flow modulator
PL2359808T3 (pl) 2006-08-09 2013-10-31 Intarcia Therapeutics Inc Osmotyczne systemy dostawcze i zespoły tłokowe
EP2157967B1 (en) 2007-04-23 2013-01-16 Intarcia Therapeutics, Inc Suspension formulations of insulinotropic peptides and uses thereof
EP2240155B1 (en) 2008-02-13 2012-06-06 Intarcia Therapeutics, Inc Devices, formulations, and methods for delivery of multiple beneficial agents
EP3323423B1 (en) 2009-09-28 2020-06-17 Intarcia Therapeutics, Inc Rapid establishment and/or termination of substantial steady-state drug delivery
US20120208755A1 (en) 2011-02-16 2012-08-16 Intarcia Therapeutics, Inc. Compositions, Devices and Methods of Use Thereof for the Treatment of Cancers
US9889085B1 (en) 2014-09-30 2018-02-13 Intarcia Therapeutics, Inc. Therapeutic methods for the treatment of diabetes and related conditions for patients with high baseline HbA1c
ES2968262T3 (es) 2015-06-03 2024-05-08 I2O Therapeutics Inc Sistemas de colocación de implantes
KR20240037175A (ko) 2016-05-16 2024-03-21 인타르시아 세라퓨틱스 인코포레이티드 글루카곤-수용체 선택적 폴리펩티드 및 이들의 이용 방법
USD860451S1 (en) 2016-06-02 2019-09-17 Intarcia Therapeutics, Inc. Implant removal tool
USD840030S1 (en) 2016-06-02 2019-02-05 Intarcia Therapeutics, Inc. Implant placement guide
AU2018206539A1 (en) 2017-01-03 2019-07-18 Intarcia Therapeutics, Inc. Methods comprising continuous administration of a GLP-1 receptor agonist and co-administration of a drug

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0012115A1 (de) * 1978-12-04 1980-06-11 Ciba-Geigy Ag Pharmazeutische Präparate zur topischen Behandlung von Virusinfektionen
US4411882A (en) * 1978-12-21 1983-10-25 Sandoz Ltd. Galenical compositions

Also Published As

Publication number Publication date
CN1202818A (zh) 1998-12-23
KR19990067028A (ko) 1999-08-16
NZ320442A (en) 1999-10-28
AU7317896A (en) 1997-05-15
AU704292B2 (en) 1999-04-15
EP0857061A1 (en) 1998-08-12
BR9611343A (pt) 1999-12-28
ZA969016B (en) 1998-04-28
GB9521805D0 (en) 1996-01-03
JP2000502990A (ja) 2000-03-14
CA2235487A1 (en) 1997-05-01
NO981864D0 (no) 1998-04-24
WO1997015289A1 (en) 1997-05-01

Similar Documents

Publication Publication Date Title
DE69104777D1 (de) Orale Arzneimittelformen von biologisch aktiven Eiweisstoffen.
BR0207776A (pt) Derivado de esterol, lipossomos compreendendo o mesmo, método de carga dos referidos lipossomos e uso dos mesmos
NO961963L (no) Mikrokapsler som inneholder suspensjoner av biologisk aktive forbindelser
HUP9603305A2 (en) [(pyrrolyl-carbonyl)-amino]-naphtalene derivatives, capable for improving biological availability of biologically active compounds
YU48666B (sh) Mometason furoat monohidrat i postupak za njegovo dobijanje
ES2088160T3 (es) Formulacion y proceso quimicos.
DK0600866T3 (da) Præparater og fremgangsmåder til identifikation af biologisk aktive molekyler
EA199800288A1 (ru) Производные 5-o-дезозаминил-6-o-метилэритронолида а, способ их получения и их применение для получения биологически активных продуктов
DK366889D0 (da) Peptidderivat
TR199701567T1 (xx) Rapamisin t�revleri.
TR199800011T1 (xx) Benzo$g] kuinolin t�revleri
RU95108590A (ru) Производные имидазола
ES2176456T3 (es) Procedimiento de preparacion de un compuesto inhibidor del vih proteasa.
EP0695171A1 (en) GONADOTROPINE CONTAINING FREEZER DRIED DROPS
AU3228789A (en) Biologically active proteins
DE3863366D1 (de) Antibiotikum vermisporin, verfahren zu dessen herstellung und dasselbe als aktiver antibakterieller wirkstoff enthaltende pharmazeutische zusammensetzung.
RU94046093A (ru) Производные 7-(2-аминоэтил)бензотиазолона, способ их получения, промежуточные соединения, фармкомпозиция
SE9501285L (sv) Förfarande för framställning av biologiskt aktiva proteiner
GR1001597B (el) Νέα βιολογικώς δραστικά παράγωγα εμπουρναμενίνης, φαρμακευτικές συν?έσεις οι οποίες περιέχουν αυτά και μέ?οδος δια την παρασκευή αυτών.
AU4515996A (en) Methods for increasing the bioavailability of biological active agents
BR9611343A (pt) Processo de solubilização d eum agente em um anfifìlico, composição, e, uso da mesma.
DE59609043D1 (de) Feste Lösungen von 1,4-Diketopyrrolopyrrolen
PY0101314A (es) Compuestos farmaceuticos
NO902626L (no) Fremgangsmaate for stabilisering av biologisk aktive forbindelser immobilisert paa faste faser.
EA199800610A1 (ru) Способ создания физиологически активных соединений